SCHEMBL15420302

SCHEMBL15420302

O=S(=O)(N[C@H]1CCCO[C@@H]1COc1ccc(-c2ccc(F)cn2)cc1)C1CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.40
GRIA2 P42262 3/20 0.39
GRM5 P41594 2/20 0.35
HSD17B10 Q99714 1/20 0.35
TNF P01375 1/20 0.35
LMNA P02545 3/20 0.34
MAPK1 P28482 1/20 0.34
RAB9A P51151 4/20 0.33
POLB P06746 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
KMT2A Q03164 1/20 0.32
ALDH1A1 P00352 2/20 0.32
USP2 O75604 1/20 0.32
HTT P42858 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
CHRM1 P11229 1/20 0.32
NPC1 O15118 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
ABL1 P00519 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15420211 0.90 GRIA2 (0.42) SCN9AGRIA2GRM5HSD17B10TNF
SCHEMBL15420407 0.89 GRIA2 (0.41) GRIA2GRM5HSD17B10TNFLMNA
SCHEMBL21795673 0.89 RAB9A (0.37) SCN9AGRIA2HSD17B10TNFLMNA
SCHEMBL15420021 0.89 RAB9A (0.37) SCN9AGRIA2HSD17B10TNFLMNA
SCHEMBL15420030 0.89 SCN9A (0.35) SCN9AGRM5HSD17B10LMNARAB9A
SCHEMBL15420860 0.88 KDM4E (0.41) TNFLMNAMAPK1ALDH1A1HTT
SCHEMBL15420767 0.83 GRM5 (0.41) GRM5HSD17B10LMNAMAPK1RAB9A
SCHEMBL15440983 0.81 GRIA2 (0.43) SCN9AGRIA2GRM5ABL1
SCHEMBL12988153 0.81 GRIA2 (0.43) SCN9AGRIA2GRM5ABL1
SCHEMBL15420297 0.80 TP53 (0.43) LMNAMAPK1POLBKMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2694472-B1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2020-03-11 EP disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF GRIN2A, GRIN2B, SLC1A2 SCN9A 648/4885GRIA2 12/4885GRM5 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.